Quidel Corp (QDEL) received a Buy rating and a $70 price target from Canaccord Genuity analyst Mark Massaro on June 26. The company’s shares closed on Friday at $59.32.
According to TipRanks.com, Massaro is a top 100 analyst with an average return of 21.3% and a 65.0% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Meridian Bioscience Inc, and Quanterix Corporation.
Quidel Corp has an analyst consensus of Moderate Buy, with a price target consensus of $72.
See today’s analyst top recommended stocks >>
Based on Quidel Corp’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $24.84 million. In comparison, last year the company had a net profit of $33.96 million.
Based on the recent corporate insider activity of 73 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2019, Kenneth Buechler, a Director at QDEL sold 2,002 shares for a total of $121,281.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Quidel Corp. engages in the development, manufacture, and market of rapid diagnostic testing solutions. Its portfolio includes rapid immunoassays, cardiac immunoassays, specialized diagnostic solutions and molecular diagnostic solutions.
